Search

Your search keyword '"Berman, Brian"' showing total 2,076 results

Search Constraints

Start Over You searched for: Author "Berman, Brian" Remove constraint Author: "Berman, Brian"
2,076 results on '"Berman, Brian"'

Search Results

52. Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)

53. Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)

54. CTNI-27. TRIAL IN PROGRESS A PHASE 2 STUDY OF BPM 31510 (AN OXIDIZED COQ10-LIPID CONJUGATE NANODISPERSION) WITH VITAMIN K AND STANDARD CHEMORADIATION IN NEWLY DIAGNOSED GLIOBLASTOMA

55. Non-motor symptoms in dystonia: from diagnosis to treatment

66. Meta-analysis of real-time fMRI neurofeedback studies using individual participant data: How is brain regulation mediated?

67. Efficacy of the iron‐chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta‐analysis.

68. Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities.

69. Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)

70. Impact of Actinic Keratosis on patient-reported AK symptoms, emotions and functioning measured using Skindex-16, among patients with Actinic Keratosis administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

71. Comparison of patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across U.S.

74. Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)

75. Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

82. List of Contributors

83. Keloids

84. Predictors of alcohol responsiveness in dystonia

85. Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2

90. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action

92. Update on Seborrheic Keratosis: Optimizing Patient Outcomes

94. An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis

96. Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis

98. Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Catalog

Books, media, physical & digital resources